- Conditions
- Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder, Autism Spectrum Disorder, Smith-Magenis Syndrome
- Interventions
- tasimelteon
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced May 22, 2026, 12:51 AM EDT